文献速递结核与非结核分枝杆菌细菌感染、耐药与抗菌药物

贝达喹啉耐药准备不足:呼吁临床与项目应对

We Are Underprepared for Bedaquiline Resistance: A Call for Clinical and Programmatic Readiness.
PubMed 文献 · Clin Infect Dis · 2026-01-01

贝达喹啉耐药威胁耐多药结核病治疗成果,高负担地区存在原发和获得性耐药,耐药病例临床结局差、死亡率高且有传播证据。本文分析耐药驱动因素,指出药敏检测在表型和基因型方面的关键缺口,呼吁加强监测、开发复合药敏标准、采用快速分子工具并确保配套药物可及。

要点

  • 贝达喹啉耐药已在多个高负担地区出现原发和获得性耐药,与不良结局和高死亡率相关。
  • 当前表型和基因型药敏检测存在延迟、灰区和异质性耐药等缺口,影响及时临床决策。
  • 需加强耐药监测、开发复合药敏标准、采用靶向二代测序等快速分子工具并保障配套药物可及。

核心结论

  • 贝达喹啉耐药威胁耐多药结核病治疗成果,需临床、项目和研究领域协同行动以保持其疗效。

主要发现

  • 监测数据显示高负担地区存在贝达喹啉原发和获得性耐药,耐药结核病与不良临床结局、高死亡率相关,并有传播证据。
  • 贝达喹啉独特药代动力学特性和当前药敏检测方法的局限性是驱动耐药趋势的因素。

临床怎么用

  • 应评估不含贝达喹啉的方案,同时加强耐药监测。
  • 应开发复合药敏检测标准并采用靶向二代测序等快速分子工具。
  • 应确保有效配套药物的公平可及和以人为中心的治疗支持。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Bedaquiline has transformed the treatment of multidrug-resistant tuberculosis (MDR-TB). However, bedaquiline resistance now threatens these gains. Emerging surveillance data demonstrate both baseline and acquired resistance across high-burden settings, with bedaquiline-resistant disease associated with poor clinical outcomes, high mortality, and growing evidence of transmission. In this Perspective, we examine the converging factors driving this trend, including bedaquiline's unique pharmacokinetic properties and limitations of current drug-susceptibility testing (DST) approaches. We describe critical gaps in phenotypic and genotypic DST, including delayed detection, diagnostic gray zones, and heteroresistance, which undermine timely clinical decision-making. We highlight the need to evaluate bedaquiline-sparing regimens alongside strengthened resistance surveillance, development of composite DST standards, and adoption of rapid molecular tools such as targeted next-generation sequencing. We emphasize the importance of equitable access to effective companion drugs and robust, person-centered treatment support. Coordinated action across clinical, programmatic, and research domains is essential to preserve bedaquiline's efficacy and future TB treatments.

来源:Clin Infect Dis,查看原文。版权归原作者所有。

引用

  1. Cross GB, Walker HN, Hasan T, et al. We Are Underprepared for Bedaquiline Resistance: A Call for Clinical and Programmatic Readiness. Clin Infect Dis. 2026. PMID: 41498255. doi:10.1093/cid/ciag008

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。